Free Newsletter
FEATURES >> The most interesting logos in Pharma
Primary care docs want samples from reps
What do doctors really prefer: A live sales rep or a computer? According to a new survey, the human being wins--at least for primary care doctors collecting drug samples. Some 73 percent of respondents in a DTW Marketing Research study said they'd rather receive hand-delivered samples than order them online. About 20 percent said they preferred e-sampling.
DTW's Christine Alongi said the results should "serve as a word of caution" to drugmakers who are overhauling their marketing operations. E-sampling might save money, but in the end "could negatively affect the overall promotional mix for the brand," Alongi said, as quoted by Medical Marketing & Media.
But these numbers contradict some other research; other studies have shown that doctors increasingly prefer online detailing, because it gives them the opportunity to log on at their leisure, rather than meet during office hours. And as MM&M points out, some drugmakers have actually seen sampling increase with online requisition.
- read the MM&M story
Related Articles:
Pfizer tops drug-sampling list with $2.7B in spending
Big change in market-access strategies, execs say
Have pharma promos gone too commercial?
Pharma reps between rock and hard place
Comments
One day the pharma industry will realise that people buy from PEOPLE - and the PEOPLE (i.e. sales rep.s) are the face of the company! GSK seem to have come to terms with that, and their new metrics against which rep.s will be measured make a lot of sense in this new environment of transparency and customer service rather than sales numbers.
And I expect that the pendulum will also swing on the outsourcing of clinical development activities too ..... for exactly the same reason.
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities



SHARE
WITH: